Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Emma Rabinovich; Kith Pradhan; R. Alejandro Sica; Lizamarie Bachier-Rodriguez; Ioannis Mantzaris; Noah Kornblum; Aditi Shastri; Kira Gritsman; Mendel Goldfinger; Amit Verma; Ira Braunschweig

doi:10.1186/s40164-021-00248-9

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Emma Rabinovich, Kith Pradhan, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Ioannis Mantzaris, Noah Kornblum, Aditi Shastri, Kira Gritsman, Mendel Goldfinger, Amit Verma, Ira Braunschweig

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Abstract

Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.

Original language	English (US)
Article number	55
Journal	Experimental Hematology and Oncology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s40164-021-00248-9
State	Published - Dec 2021

Keywords

CAR T-cell therapy
DLBCL
LDH

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40164-021-00248-9

Cite this

Rabinovich, E., Pradhan, K., Sica, R. A., Bachier-Rodriguez, L., Mantzaris, I., Kornblum, N., Shastri, A., Gritsman, K., Goldfinger, M., Verma, A., & Braunschweig, I. (2021). Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort. Experimental Hematology and Oncology, 10(1), Article 55. https://doi.org/10.1186/s40164-021-00248-9

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort. / Rabinovich, Emma; Pradhan, Kith ; Sica, R. Alejandro et al.
In: Experimental Hematology and Oncology, Vol. 10, No. 1, 55, 12.2021.

Research output: Contribution to journal › Letter › peer-review

Rabinovich, E, Pradhan, K , Sica, RA, Bachier-Rodriguez, L, Mantzaris, I , Kornblum, N , Shastri, A , Gritsman, K , Goldfinger, M , Verma, A & Braunschweig, I 2021, 'Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort', Experimental Hematology and Oncology, vol. 10, no. 1, 55. https://doi.org/10.1186/s40164-021-00248-9

@article{dafc260cedee4333ba8e7214fefba613,

title = "Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort",

abstract = "Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.",

keywords = "CAR T-cell therapy, DLBCL, LDH",

author = "Emma Rabinovich and Kith Pradhan and Sica, {R. Alejandro} and Lizamarie Bachier-Rodriguez and Ioannis Mantzaris and Noah Kornblum and Aditi Shastri and Kira Gritsman and Mendel Goldfinger and Amit Verma and Ira Braunschweig",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s40164-021-00248-9",

language = "English (US)",

volume = "10",

journal = "Experimental Hematology and Oncology",

issn = "2162-3619",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

AU - Rabinovich, Emma

AU - Pradhan, Kith

AU - Sica, R. Alejandro

AU - Bachier-Rodriguez, Lizamarie

AU - Mantzaris, Ioannis

AU - Kornblum, Noah

AU - Shastri, Aditi

AU - Gritsman, Kira

AU - Goldfinger, Mendel

AU - Verma, Amit

AU - Braunschweig, Ira

PY - 2021/12

Y1 - 2021/12

N2 - Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.

AB - Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.

KW - CAR T-cell therapy

KW - DLBCL

KW - LDH

UR - http://www.scopus.com/inward/record.url?scp=85120961376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120961376&partnerID=8YFLogxK

U2 - 10.1186/s40164-021-00248-9

DO - 10.1186/s40164-021-00248-9

M3 - Letter

AN - SCOPUS:85120961376

SN - 2162-3619

VL - 10

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

IS - 1

M1 - 55

ER -